Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Queensland Health
Chubb
US Army
Express Scripts
QuintilesIMS
Julphar
Boehringer Ingelheim

Generated: June 25, 2018

DrugPatentWatch Database Preview

ARCAPTA NEOHALER Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Arcapta Neohaler patents expire, and when can generic versions of Arcapta Neohaler launch?

Arcapta Neohaler is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has eighty-four patent family members in thirty-eight countries.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Two suppliers are listed for this compound. Additional details are available on the indacaterol maleate profile page.
Drug patent expirations by year for ARCAPTA NEOHALER
Pharmacology for ARCAPTA NEOHALER
Synonyms for ARCAPTA NEOHALER
(6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H- pyrido(3,2-b)-1,4-oxazin-4-yl)methyl dihydrogen phosphate
(R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
(R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
2(1H)-Quinolinone,5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-
2474AH
2JEC1ITX7R
312753-06-3
435273-74-8
5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one
5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one
5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-2(1H)-quinolinone Maleic Acid
5-[(1R)-2-[(5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO]-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE
5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; QAB 149
5-[(1R)-2-[(5,6-diethylindan-2-yl)amino]-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one
5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1h-quinolin-2-one
5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate
5-{(1R)-2-((5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one
5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one
5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one (2Z)-but-2-enedioate
5,6-diethyl-N-[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]indan-2-aminium (2Z)-3-carboxyacrylate
753498-25-8
753I063
8-Hydroxy-5-[(R)-1-hydroxy-2-(5,6-diethylindan-2-ylamino)-ethyl]-1H-quinolin-2-one
870265-20-6
8OR09251MQ
AB0073003
AB01565805_02
ABP001015
AC-27668
AC1OCFKW
AJ-92125
AK160051
AK163936
AKOS024463516
AKOS024464878
AN-488
API0008161
Arcapta
Arcapta neohaler (TN)
AS-10152
AX8161417
BCP0726000140
BCP9000787
BDBM50318159
C24H28N2O3.C4H4O4
CHEBI:68573
CHEBI:68575
CHEMBL1095777
CHEMBL1789842
CS-0744
CS-2703
D03DJL
D03VWV
D09318
D09319
DB05039
DTXSID90185198
FT-0686953
FT-0773084
GTPL7455
Hirobriz Breezhaler
HY-14299
HY-14299A
I0927
Indacaterol
Indacaterol (maleate)
Indacaterol (USAN/INN)
Indacaterol [USAN:INN:BAN]
Indacaterol maleate
Indacaterol maleate (JAN/USAN)
Indacaterol maleate [USAN]
Indacaterol Maleic Acid Salt
Indacaterol/mometasone
IREJFXIHXRZFER-PCBAQXHCSA-N
J-521526
KB-77887
MFCD18782702
MFCD20526769
MolPort-023-219-171
MolPort-035-395-723
Onbrez
Onbrez Breezhaler
Onbrez Inhalation Capsules
Oslif Breezhaler
Q-4501
QAB 149
QAB 149 Maleic Acid
QAB 149AFA
QAB-149
QAB-149 maleate
QAB-149-AFA
QAB149
QAB149-AFA
QABI49
QMF149
QZZUEBNBZAPZLX-QFIPXVFZSA-N
RL03096
S3083
SC-90142
SCHEMBL48098
SCHEMBL523627
UNII-2JEC1ITX7R
UNII-8OR09251MQ
W9904
ZINC35801098

US Patents and Regulatory Information for ARCAPTA NEOHALER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sunovion Pharms Inc ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Sunovion Pharms Inc ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Sunovion Pharms Inc ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for ARCAPTA NEOHALER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,436,017 Beta-2-adrenoreceptor agonists ➤ Sign Up
7,622,483 .beta.2-adrenoceptor agonists ➤ Sign Up
8,283,362 Beta-2-adrenoreceptor agonists ➤ Sign Up
9,040,559 BETA2-adrenoceptor agonists ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ARCAPTA NEOHALER

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
393 Luxembourg ➤ Sign Up PRODUCT NAME: GLYCOPYRRONIUM OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL BROMURE, COMBINE A INDACATEROL OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL MALEATE. FIRST REGISTRATION: 20130923
7/2010 Austria ➤ Sign Up PRODUCT NAME: INDACATEROL UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON
1183240/01 Switzerland ➤ Sign Up FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
2014000025 Germany ➤ Sign Up PRODUCT NAME: GLYCOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON (KOMPONENTE 1) UND INDACATEROL ODER EIN DERIVAT HIERVON ODER EIN SALZ VON INDACATEROL ODER EINEM DERIVAT HIERVON (KOMPONENTE 2); REGISTRATION NO/DATE: EU/1/13/862 20130919
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Baxter
Dow
Argus Health
Chubb
US Army
Farmers Insurance
Citi
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.